ProfileGDS5678 / 1422478_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 64% 64% 69% 64% 64% 64% 71% 79% 64% 64% 64% 63% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8127963
GSM967853U87-EV human glioblastoma xenograft - Control 23.8521864
GSM967854U87-EV human glioblastoma xenograft - Control 33.858864
GSM967855U87-EV human glioblastoma xenograft - Control 44.2853769
GSM967856U87-EV human glioblastoma xenograft - Control 53.8059264
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8934764
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9109964
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4325371
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.506279
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8512664
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8435664
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.836264
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7867963
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8381464